Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 20;14:1092668. doi: 10.3389/fimmu.2023.1092668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Yang, Xiao, Ma, Li, Ran, Yang, Yang, Fu and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The potential mechanism of preconditioned MSCs and EVs in treating AD and psoriasis. SOD3-transduced MSCs can alleviate the allergic inflammation in keratinocytes through competitively interacting with H4R and IL-4Rα. SOD-MSCs can reduce the inflammation in the skin through the NFκB, MAPK, and JAK-STAT pathways. HGF-transduced MSCs can ameliorate psoriasis-like erythema, scaling, and thickening and the expression of CK6 and CK17 and decrease pro-inflammatory cytokines such as IFN-γ, IL-6, and TNF-α. Preconditioned with the TLR3 agonist poly I:C or IFN-γ can ameliorate more epidermal thickness and inflammatory cell infiltration in skin lesions. IFNγ-sEVs can decrease pro-inflammatory cytokines including IL-17A, IFN-γ, IL-6, and TNF-α and Th17 cells and increase the population of Th2.